New study [1] below.
... "Serum 25-(OH)D was lower in patients with prostate cancer."
... "Moreover, serum 25(OH)D was {lowest} in patients with severe prostate cancer ..."
... "serum C-reactive protein (CRP) and interleukin (IL)-8, two inflammatory molecules, were elevated in patients with prostate cancer"
... "Serum 25-(OH)D was negatively correlated with serum CRP and IL-8 in patients with prostate cancer."
Conclusion: "Inflammation may be an important mediator for prostate cancer progression in patients with low vitamin D status."
From a 2010 vitamin D / PCa paper [2]:
"Functional analysis by pathway or Gene Set Analysis revealed early suppression of WNT, Notch, NF-kB, and IGF1 signaling. Transcripts related to inflammation were suppressed at 6 h (e.g. IL-1 pathway) and suppression of proinflammatory pathways continued at later time points (e.g. IL-17 and IL-6 pathways)."
Suppression of NF-kB would be sufficient to lower inflammation IMO.
It's good to see confirmation in a human study.
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/284...
Oncotarget. 2017 Mar 28;8(13):22076-22085. doi: 10.18632/oncotarget.16195.
Low vitamin D status is associated with inflammation in patients with prostate cancer.
Xie DD1, Chen YH2, Xu S1, Zhang C3, Wang DM1, Wang H3, Chen L1, Zhang ZH3, Xia MZ4, Xu DX3, Yu DX1.
Author information
1
Department of Urology, Second Affiliated Hospital, Anhui Medical University, Hefei 230022, China.
2
Department of Histology and Embryology, Anhui Medical University, Hefei 230032, China.
3
Department of Toxicology, Anhui Medical University, Hefei 230032, China.
4
Life Science College, Anhui Medical University, Hefei 230032, China.
Abstract
Vitamin D deficiency has been associated with increased risks of prostate cancer. Nevertheless, the mechanisms remain unclear. The aim of this study was to analyze the association among prostate cancer, vitamin D status and inflammation. Sixty patients with newly diagnosed prostate cancer and 120 age-matched controls were recruited for this study. Vitamin D status was evaluated and serum inflammatory molecules were measured. Serum 25-(OH)D was lower in patients with prostate cancer. Moreover, serum 25(OH)D was lower in patients with severe prostate cancer than patients with mild and moderate prostate cancer. By contrast, serum C-reactive protein (CRP) and interleukin (IL)-8, two inflammatory molecules, were elevated in patients with prostate cancer. Serum 25-(OH)D was negatively correlated with serum CRP and IL-8 in patients with prostate cancer. Additional analysis showed that the percentage of vitamin D receptor positive nucleus in the prostate was reduced in patients with prostate cancer. By contrast, the percentage of nuclear factor kappa B p65-positive nucleus was elevated in patients with prostate cancer. Our results provide evidence that there is an association among prostate cancer, vitamin D deficiency and inflammatory signaling. Inflammation may be an important mediator for prostate cancer progression in patients with low vitamin D status.
KEYWORDS:
inflammation; nuclear factor kappa B p65; prostate cancer; vitamin D deficiency; vitamin D receptor
PMID: 28423553 DOI: 10.18632/oncotarget.16195
[2] ncbi.nlm.nih.gov/pubmed/?te...
BMC Genomics. 2010 Jan 13;11:26. doi: 10.1186/1471-2164-11-26.
1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1.
Kovalenko PL1, Zhang Z, Cui M, Clinton SK, Fleet JC.
Author information
1
Department of Foods and Nutrition and the Interdepartmental Nutrition Program, Purdue University, West Lafayette, IN 47907-2059, USA.
Abstract
BACKGROUND:
Prostate cancer is the second leading cause of cancer mortality among US men. Epidemiological evidence suggests that high vitamin D status protects men from prostate cancer and the active form of vitamin D, 1alpha,25 dihydroxyvitamin D3 (1,25(OH)2D) has anti-cancer effects in cultured prostate cells. Still, the molecular mechanisms and the gene targets for vitamin D-mediated prostate cancer prevention are unknown.
RESULTS:
We examined the effect of 1,25(OH)2D (+/- 100 nM, 6, 24, 48 h) on the transcript profile of proliferating RWPE1 cells, an immortalized, non-tumorigenic prostate epithelial cell line that is growth arrested by 1,25(OH)2D (Affymetrix U133 Plus 2.0, n = 4/treatment per time and dose). Our analysis revealed many transcript level changes at a 5% false detection rate: 6 h, 1571 (61% up), 24 h, 1816 (60% up), 48 h, 3566 (38% up). 288 transcripts were regulated similarly at all time points (182 up, 80 down) and many of the promoters for these transcripts contained putative vitamin D response elements. Functional analysis by pathway or Gene Set Analysis revealed early suppression of WNT, Notch, NF-kB, and IGF1 signaling. Transcripts related to inflammation were suppressed at 6 h (e.g. IL-1 pathway) and suppression of proinflammatory pathways continued at later time points (e.g. IL-17 and IL-6 pathways). There was also evidence for induction of anti-angiogenic pathways and induction of transcripts for protection from oxidative stress or maintenance of cell redox homeostasis at 6 h.
CONCLUSIONS:
Our data reveal of large number of potential new, direct vitamin D target genes relevant to prostate cancer prevention. In addition, our data suggests that rather than having a single strong regulatory effect, vitamin D orchestrates a pattern of changes within prostate epithelial cells that limit or slow carcinogenesis.
PMID: 20070897 PMCID: PMC2820456 DOI: 10.1186/1471-2164-11-26
[Indexed for MEDLINE] Free PMC Article